04 Nov, 2021
Galecto Reports Third Quarter Operating and Financial Results
Announces clinical collaboration with Roche for first line NSCLC Remains on track with clinical data milestone timing BOSTON , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and
26 Oct, 2021
Galecto to Present at Upcoming Investor Conferences
BOSTON , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Galecto’s management team will be presenting virtually at the Credit Suisse Healthcare
15 Sep, 2021
Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference
BOSTON , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, the Company’s Chief Executive Officer, will be presenting on Tuesday,
05 Aug, 2021
Galecto Reports Second Quarter Operating and Financial Results
BOSTON , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30, 2021 .